DoH, Penn Medicine sign MoU on translational research, second labs in Abu Dhabi


ABU DHABI: Ahead of its participation at BIO International Convention, in San Diego, USA, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector, signed a second Memorandum of Understanding (MoU) with the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine) to expand cooperation in education, research and innovation programmes. Both parties will further collaborate on translational research ecosystem development as well as launch innovative collaborative research involving ‘second labs’ that leverage and build capabilities in Abu Dhabi and at Penn Medicine in Philadelphia, Pennsylvania, USA in leading-edge areas of science.

The MoU has been signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi and Mick Merritt, Chief Operating Officer and Lead for Global Clinical Programmes, at Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).

Reinforcing the Emi
rate’s strategy to be a leading destination for life sciences, this second MoU establishes that the DoH and Penn Medicine seek to design and develop a translational medicine ecosystem based on Penn’s Institute for Translational Medicine and Therapeutics (ITMAT) that will enable Abu Dhabi to leverage and expand upon the strengths of existing organisations. In addition, the MoU seeks to explore the potential of launching two multi-year collaborative research programmes. One focuses on the expanded application of artificial intelligence (AI) to identify new potential antibiotics. The other focuses on longitudinal follow-up and genetic analysis of people with Alzheimer’s in Abu Dhabi that will facilitate cross-population comparative analysis and unique attributes that ultimately enable prevention and early diagnosis.

With the aim of bridging the gap between preliminary research and practical applications in medical practices, translational research seeks to translate research discoveries from laboratory findings
and clinical studies into practical applications to improve human health.

Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi, said, ‘With a successful history of collaboration with Penn Medicine, the Department of Health – Abu Dhabi is thrilled to build on this partnership which underscores the crucial importance of synergy between academia and regulatory bodies in enabling research development and innovation. Abu Dhabi continues to spearhead global collaboration on the global stage and facilitate knowledge and experience sharing in reflection of its commitment to driving forward a future where innovative healthcare solutions are accessible to all.’

Leveraging Abu Dhabi’s advanced infrastructure and Penn Medicine’s renowned expertise in discovering and developing novel treatments, the collaboration will potentiate the development of a translational medicine and therapeutics ecosystem to further enable capacity development and the cre
ation of novel discoveries and treatments to be developed in Abu Dhabi. This will involve the development of research training and educational programmes for healthcare professionals to upskill the workforce in various healthcare domains including medical science, biomedical research and health technology.

Glen Gaulton, PhD, Vice Dean and Director of the Center for Global Health at Penn’s Perelman School of Medicine, said, ‘Penn Medicine has become a global leader in precision medicine and innovation that has resulted in more than 25 new drugs and therapies approved by the U.S. Food and Drug Administration in the past several years. These accomplishments were catalysed by the transformational investment in ITMAT 20 years ago, which has developed a translational research ecosystem that enriched our human capital and incentivised interdisciplinary and translational research. We look forward to collaborating with our colleagues in Abu Dhabi to replicate this structure in parallel with investment in ‘second labs
‘ to foster interactions focused on specific challenges and opportunities in translational research. This will advance the capacity of Abu Dhabi to pursue its vision to become a true innovator in the biomedical sciences and a regional leader that will make a global impact.’

Led by the Department of Health – Abu Dhabi (DoH), a high-profile Abu Dhabi delegation headed by Mansoor Ibrahim Al Mansoori, Chairman of the DoH, visited the USA between 29th May,2024 and 5th June,2024 to showcase the Emirate’s partnership opportunities and explore collaboration with leading organisations in Research and Development (R and D), manufacturing and innovation. Kicking off in Philadelphia, delegates have met with existing and new partners to foster collaboration with leading education research institutions, governmental bodies and health-tech giants. The transnational mission has culminated in San Diego, coinciding with Abu Dhabi’s participation at BIO International Convention 2024 to exhibit the Emirate’s growth and developm
ent of its biotechnology industry. The participation has witnessed in-depth discussions, shared insights and expertise as well as explored collaborations in health-tech, life science and innovation.

Highlighting the rich diversity and expertise within Abu Dhabi’s ecosystem, the Delegation comprised of 20 key entities including the Department of Health – Abu Dhabi (DoH), Abu Dhabi Investment Office (ADIO), Abu Dhabi Executive Office (ADEO), G42, Masdar City, Mubadala Investment Company, Khalifa Economic Zones Abu Dhabi Group (KEZAD), Malaffi, The Medical Office, Ambulatory Healthcare Services, PureHealth, One Health, M42, Technology Innovation Institute (TII), Burjeel Holdings, Khalifa University, Abu Dhabi Holding Company (ADQ), Abu Dhabi Stem Cell Centre (ADSCC) and Etihad Airways.

Source: Emirates News Agency

du to launch hyperscale cloud, sovereign AI services for UAE government


DUBAI: du, from Emirates Integrated Telecommunications Company (EITC), today announced it will deploy Oracle Alloy to offer hyperscale cloud and sovereign AI services for the government and public sector entities in the UAE focusing on Dubai and the Northern Emirates.

The signing ceremony took place during the AI Retreat in Dubai, attended by decision-makers, industry leaders, AI experts from government and private sectors and global tech giants to discuss strategies, challenges and opportunities presented by AI locally and globally.

Oracle Alloy is a complete cloud infrastructure platform that enables Oracle partners to become cloud providers.

With this platform, du can provide more than 100 Oracle Cloud Infrastructure (OCI) services together with its own value-added cloud services and applications. This will enable du to become the first local hyperscale cloud provider to offer a comprehensive set of cloud services branded under its portfolio.

The services will be customised to meet the specific needs o
f the UAE markets and industry verticals while ensuring alignment with the UAE regulatory requirements.

du will also benefit from Oracle and NVIDIA’s collaboration, enabling du to offer sovereign AI capabilities and its new GPU-as-a-Service to government entities in Dubai and Northern Emirates.

Oracle’s distributed cloud, AI Services, and generative AI services, combined with NVIDIA’s accelerated computing platform and software, will enable du to quickly deploy AI capabilities for its public sector customers.

Fahad Al Hassawi, CEO of du, said, “The UAE is one of the fastest-growing cloud services markets in the world, and public sector entities in the UAE are rapidly embracing the benefits of the cloud, including added agility, efficiency, security, and access to the latest digital technologies such as AI and machine learning.”

Source: Emirates News Agency

MoHAP launches tobacco-free workplace guide


DUBAI: The Ministry of Health and Prevention (MoHAP) has launched a tobacco-free workplace guide as part of its ongoing efforts to combat smoking in all forms, protect community members from the public health dangers associated with smoking, and improve the quality of life in work environments.

The handbook, developed by the Ministry’s National Tobacco Control Program, offers a comprehensive explanation of the measures implemented to create a tobacco-free workplace.

It outlines the detrimental effects of smoking on individual health and the environment, along with the benefits of quitting. Additionally, the guide provides practical instructions for managers and employees on establishing a smoke-free environment, detailing procedures for handling violations, and offering steps to assist employees in quitting smoking.

The UAE is considered one of the leading countries in tobacco control, having enacted Federal Law No. 15 of 2009 on Combating Tobacco, followed by comprehensive executive regulations governing
all tobacco-related activities. These regulations aim to ban smoking in enclosed public spaces and prohibit the use of tobacco in any form in various public areas, including government buildings, healthcare and educational institutions, and public transportation, among others.

Effective measures

Dr. Hussain Abdul Rahman Al Rand, Assistant Under-Secretary for the Public Health Sector, stated: “MoHAP’s Tobacco-Free Workplace Guide will be used as a key resource and tool to assist both government and private entities in fostering a workplace free from the use of all tobacco products. It also comes in line with the UAE’s commitment to the WHO Framework Convention on Tobacco Control (WHO FCTC), ratified in 2005, aiming to implement effective measures that protect against exposure to tobacco smoke in workplaces, public transportation, and public places.”

Reducing tobacco consumption

Dr. Hussein Al Rand highlighted MoHAP’s extensive initiatives to combat tobacco use, ranging from monitoring and tracking tobacco
consumption to protecting community members from exposure to smoking. These initiatives extend to providing cessation services, educating the public on the harms of tobacco, and enforcing bans on tobacco advertising. Additionally, he underscored the Ministry’s support for the government’s decision to implement an excise tax on tobacco products starting in 2019.

He noted that these efforts have successfully decreased the tobacco consumption rate from 11.1 percent in 2010 to 9.1 percent in 2018, as reported by the National Health Survey. Dr. Al Rand also highlighted that the UAE is on track to meet the Global NCD Action Plan 2025, achieving a significant reduction in tobacco use prevalence in recent years, as documented in the World Health Organisation’s latest global report on tobacco trends.

Source: Emirates News Agency

Nahyan bin Mubarak inaugurates ART Fertility Clinic in Al Ain City


AL AIN: Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance and Coexistence, affirmed that the UAE earned a distinguished reputation on a global scale in the field of healthcare, thanks to the great support and dedication of the UAE’s wise leadership, represented by President His Highness Sheikh Mohamed bin Zayed Al Nahyan, who always emphasises the importance of this vital sector and its importance to the UAE’s progress and development.

Sheikh Nahyan emphasised that the UAE makes no compromises in its efforts to upgrade this sector constantly, whether by engaging the best medical expertise globally or acquiring the newest equipment and technology for use in public or private hospitals.

Sheikh Nahyan made this statement during his inauguration of the ART Fertility Clinic in Al Ain, which was attended by various state-level officials and medical specialists, including Dr. Noura Khamis Al Ghaithi, Undersecretary of Department of Health – Abu Dhabi (DoH), Dr. Amal Al Qubaisi, former speaker of Federal N
ational Council, Eng. Ali Khalifa Al Qamzy, Director General of Al Ain City Municipality, Abdulnasser Alshaali, UAE Ambassador to India, and Hareb Al Darmaki, Chairman of Gulf Capital.

Sheikh Nahyan visited all departments of the clinic, praising the unique equipment in each department and wishing success to all health facilities in the UAE in providing the best medical service of international standards to the nationals of the UAE, and residents of its blessed land.

He added “This world-class clinic raises the bar for IVF services and will be a gift to the population of Al Ain. It is also a testament to ART Fertility’s commitment to the UAE both in terms of providing the latest technology and attracting world-renowned medical staff in the field of reproductive medicine’.

Situated strategically within Al Ain, the new clinic promises easy accessibility for residents not only in Al Ain but also from the neighbouring Emirates. The state-of-the-art clinic in Al Ain deploys the most advanced infrastructure and
technology including AI equipped incubators, the latest Operating Room (OR) facilities, a genetic test facility, and an in-house pathology lab. The 25,000 square feet facility will provide all services related to Reproductive Medicine including treating male and female infertility including all related medical procedures, diagnosing, and treating genetic disorders. This latest addition to ART Fertility’s growing network embodies the institution’s commitment to offering comprehensive fertility treatments, undertaking root-cause analysis of infertility via proprietary research, and making the UAE an internationally recognized referral centre for reproductive medicine.

Established in 2015, ART Fertility Clinics, formerly known as IVI Middle East, underwent a transformative journey in 2019 when Gulf Capital led the carve out from IVI RMA and rebranded it as ART Fertility Clinics. Since then, ART Fertility Clinics has become the leading

IVF clinics in the GCC with presence in Abu Dhabi, Al Ain, and Dubai. Additi
onally, ART Fertility Clinics operates ten advanced clinics in India, positioning itself as a global leader in reproductive medicine.

Dr. Karim El Solh, Chairman of ART Fertility and CEO of Gulf Capital, remarked, ‘We are delighted to open a new, full-fledged IVF Fertility clinic in Al Ain, equipped with the latest advanced technology and facilities for treating infertility and genetic disorders. Gulf Capital is focused on bringing the best healthcare services to Al Ain following successful expansions in Abu Dhabi and Dubai. ART Fertility has now expanded, with the help of Gulf Capital, from a single clinic in Abu Dhabi to 14 locations across the GCC and India. ART Fertility has become today one of the largest independent IVF Fertility platforms across the Gulf region.’

Prof Human Fatemi, Prof. of Reproductive Medicine, and Group Medical Director at ART Fertility Clinics, with over 200 research papers to his credit, added, ‘ART Fertility Clinics has an extremely talented and experienced team of world-renown
ed physicians, embryologists, and medical professionals including counsellors and nursing staff that help us achieve one of the highest success rates globally as well as extremely low rate of complications.”

Mr. Suresh Soni, Chief Executive Officer of ART Fertility Clinics, expressed his enthusiasm for the expansion, stating, “We are dedicated to extending our reach to provide cutting-edge reproductive healthcare solutions to individuals and couples across the region. The opening of our Al Ain clinic marks another significant milestone in our mission to make advanced fertility treatments accessible to those in need. ART Fertility Clinics is planning additional Clinics across Kingdom of Saudi Arabia by year end 2024.’

Source: Emirates News Agency

MOHAP announces defined cases of permissible abortion, their controls and procedures


ABU DHABI: The Ministry of Health and Prevention (MOHAP) has announced the defined cases of permissible abortion and their controls and procedures, to preserve the pregnant woman’s life, ensure her safety, and enhance oversight of healthcare facilities operating in the UAE.

The Ministry has affirmed that new controls and procedures were issued to define and regulate cases of permissible abortion in the UAE. The new regulation stipulates that the decision on abortion requests shall be made by a dedicated committee that will be formed within each health authority by a decision of MOHAP or the head of the emirate’s health authority.

The committee should comprise 3 doctors, one of them is an obstetrics and gynecology specialist, the second is a psychiatry specialist, in addition to a representative of the Public Prosecution. The Committee is permitted to consult a third party with the appropriate specialty and expertise when needed.

The Ministry stated that conducting an abortion procedure is permissible if co
ntinuing the pregnancy endangers the pregnant woman’s life, in the absence of any alternative way to save her life, or if the fetus’s deformation is severe, proven, and will affect the newborn’s health and life. This case should be supported by a medical report issued by a specialised medical committee. Several other cases of permissible abortion have been defined, provided that the gestational period at the time of the abortion procedure does not exceed 120 days.

The regulation stipulates also that the abortion procedure should be performed only in a healthcare facility licensed by the competent health authority to perform abortions, the procedure should be performed by a specialist obstetrician-gynecologist licensed to practice within the country, and the abortion should be free of any medical complications which may put the pregnant woman’s life at high risk.

The relevant healthcare authorities are committed to developing a policy that details the responsibilities and obligations of the healthcare facili
ties and medical staff in charge of the abortion procedure for the above-mentioned cases. It should detail also the rights and responsibilities of the pregnant woman subject to the abortion procedure, and explain to her the necessary health care requirements before and after the abortion procedure. Healthcare facilities in the UAE have also been obligated, by the new controls, to maintain the privacy and confidentiality of the personal data of a pregnant woman undergoing an abortion. Additionally, it is the responsibility of the health authority to monitor and supervise the activities of the healthcare facilities licensed to perform abortions and evaluate their compliance.

Source: Emirates News Agency

Health Min. technical cmte in preparation to estbalish multiple sclerosis center


KUWAIT, Minister of Health Dr. Ahmad Al-Awadhi announced Tuesday the formation of a technical committee in prepare for establishing a center specialized in treating multiple sclerosis (MS) within the Al-Sabah Medical District, which should include a scientific research department.



During a celebration held by the Kuwait Synthetic Sclerosis Patients Association, marking World Syndrome Day, which coincides on May 30th annually, Minister Al-Awadhi said that the Ministry will spare no effort in helping (neurosclerosis) patients.



Al-Awadhi added that the State of Kuwait is “one of advanced countries in treating MS and provides neurological clinics in all hospitals, as well as keeping up with the latest treatments,” stressing keenness to meet the needs and requirements of patients and reach the highest quality standards in the service provided.



The minister noted, “the Sclerosis Patients Association serves more than three thousand patients and has been spreading awareness in Kuwaiti society since its founding in 2010.” For his part, Chairman of the Board of Directors of the Kuwait Sclerosis Patients Association, Yosef Al-Kandari, praised the “distinguished services” provided by the Health Ministry to MS patients, including all treatments, hoping as well to speed up the establishment of this specialized center.





Source: Kuwait News Agency



Department of Health – Abu Dhabi partners with Pfizer to advance research in Sickle Cell Disease and beyond


ABU DHABI: The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Pfizer Gulf FZ LLC, a global pharmaceutical company during BIO 2024 International Convention.

Under the declaration, the entities will work to enhance Abu Dhabi’s position as leading global hub for healthcare, life science and innovation. Leveraging the Emirate’s unique capabilities and future-forward data services as well as Pfizer’s global capabilities, the parties seek to advance research through the generation and analysis of real-world data (RWD) initially focusing on Sickle Cell Disease (SCD) and expanding to other disease areas for the benefit of patients locally, regionally and beyond.

SCD is a significant public health concern in the Gulf Cooperation Council countries with prevalence rates ranging from 0.24% to 5.8%. SCD can lead to pain throughout the body and serious damage to organs, such as the heart and kidneys. The disease often disrupts
daily life, affects patients’ ability to work and substantially impairs their health-related quality of life.

In the presence of Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH) the MoU was signed by Dr Asma Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH and Serhat Yalcinkaya, Pfizer’s Gulf Cluster Lead.

Dr Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center at the DoH said, ‘The collaboration between the DoH and Pfizer represents a significant step towards harnessing real-world data in the region and better understanding patient populations from the vast available data in Abu Dhabi. By partnering with Pfizer on real-world data, we aim to drive advancements in healthcare prediction, prevention, personalised treatment and access, not only benefiting healthcare professionals and patients in Abu Dhabi, but also contributing to the improvement of care for patients globally.’

The two entities will work together to advance
Abu Dhabi’s RWD capabilities by promoting global knowledge exchange and education of scientific ideas. Excellence in the delivery of healthcare services remains at the forefront of DoH’s priorities, as it strives to continuously enhance the quality of care through rolling out specialised and personalised healthcare services in line with international standards and best practices. The agreement will focus on upskilling the local healthcare workforce on RWD by establishing a dynamic and sustainable partnership model promoting education and awareness on real-world evidence (RWE) generation, collection and analysis in order to address unmet patient needs.

Dr. Asma Ibrahim Al Mannaei continued, “Under the directives of our wise leadership, our Emirate continues to be a strong proponent of collaborative research and innovation in our mission to establish Abu Dhabi as the next generation hub for health and life science. We are committed to collaborating with our partners to harness the unique potential real-world d
ata offers to unlock actionable healthcare insights not typically garnered from traditional clinical trials. These insights will drive advancements in precise and personalised health solutions, accelerating the move from reactive to proactive care.’

Serhat Yalcinkaya, Pfizer Gulf Cluster Lead commented, “It is a significant moment for Pfizer Gulf as we sign this Memorandum of Understanding with the Department of Health. This collaboration is not just a testament to our shared vision but also a strategic step towards enhancing healthcare innovation in the Gulf region. Through this MoU, we are committed to leveraging Real-World Data initially focusing on Sickle Cell Disease landscape and exploring further to other disease areas, ultimately improving patient outcomes and transforming Abu Dhabi into a global hub for life sciences. We are proud to partner with the Department of Health and look forward to the positive impact our joint efforts will bring to the communities we serve.”

Led by DoH, a high-profile Abu
Dhabi delegation is visiting the United States of America between 29 May 2024 and 7 June 2024. The delegation will showcase the Emirate’s diversified set of unique capabilities including its world-class infrastructure, intelligent healthcare system, genome oasis, and best-in-class science, technology and talent supporting research, development and clinical trials. DoH is issuing a global invitation to explore partnership opportunities with trailblazing organisations across academia, biotech and pharmaceuticals to unlock opportunities that will improve outcomes and patient quality of life around the world.

The mission will culminate in San Diego, coinciding with DoH’s participation at BIO International Convention 2024 to exhibit Abu Dhabi’s full potential as a hub for the next generation of health and life science innovation.

Source: Emirates News Agency

DHA, Jaheziya partner to upgrade Dubai’s emergency, health crisis management system


DUBAI: The Dubai Health Authority (DHA) has signed a Memorandum of Understanding (MoU) with National Training (Jaheziya) to prepare and train medical and specialised personnel, enhance their capabilities and efficiency to handle emergencies, disasters, and health crises according to international standards and protocols.

The MoU was signed by Dr. Khaled Abdullah Lootah, Public Health Consultant and Director of the Disaster and Crisis Centre at the Dubai Health Authority, and Dr. Adel Al Shamry Al Ajami, CEO of the UAE Readiness and Medical Response Programme and Director-General of the National Training (Jaheziya).

The memorandum outlines expanding cooperation between the parties regarding the implementation of training plans to qualify individuals and medical institutions in the healthcare sector (government and private) based on the training needs and requirements approved by the Authority, using the best and latest global methods and approaches in safety, emergency preparedness, crisis management, and he
alth disaster areas.

Dubai Health Authority and the National Training (Jaheziya) extended their cooperation to include launching advanced training programmes across Dubai, focusing on emergency preparedness and crisis management in alignment with each entity’s legislation, procedures, and current systems.

Furthermore, the MoU allows for organising scientific seminars, joint workshops, specialised activities, and events in the field of emergency preparedness and crisis management. It also involves providing necessary training, technical, and logistical services to support Dubai Health Authority’s vital efforts in this area.

Under the MoU, National Training (Jaheziya) will provide access to a fully equipped field hospital to conduct simulated exercises and training programmes.

In the realm of research and collaboration efforts, Dubai Health Authority and the National Training (Jaheziya) will begin knowledge exchange in both clinical and non-clinical fields. The parties will also focus on improving services
and implementing workshops on research methodologies. Several innovation-related projects in healthcare will be launched.

Source: Emirates News Agency

Burjeel Holdings, Colombia’s Keralty announce joint venture for healthcare solutions in MENA


BOGOTÁ: Burjeel Holdings PLC today signed a Joint Venture Framework Agreement to create a joint venture (AL KALMA) with Keralty S.A.S, a multinational health organisation based in Colombia.

The agreement, signed in Cartagena de Indias, Colombia, aims to enhance well-being throughout the value chain by promoting access to high-quality healthcare at an affordable cost.

AL KALMA, a name that signifies ‘united for health and well-being’, will consolidate a unique value-based healthcare model with specialised primary care centres, health risk management, and a new range of integrated mental health services, expecting to reach nearly 30 million patients over the next decade.

The partnership combines the experience and knowledge of both groups for a rapid roll-out in the Middle East, with the potential to extend subsequently into North Africa.

The joint venture will debut in Saudi Arabia, leveraging the shift in the Saudi healthcare market towards a primary healthcare model. The collaboration aims to extend serv
ices beyond the region by evaluating each market and executing the strategy country-by-country.

The partnership announcement ceremony was attended by Mohammed Abdullah bin Khater Al Shamsi, UAE Ambassador to the Republic of Colombia, Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, John Sunil, CEO of Burjeel Holdings, Joseba Grajales, President of Keralty, and Dr. Emilio Herrera, CHO of Keralty.

Dr. Vayalil said the project envisions comprehensive well-being, from prevention to control and care of disease, to enhance services and patient outcomes on a local, personalised level.

The joint venture partnership will be operated through a newly formed holding company established in the Abu Dhabi Global Market jurisdiction. Burjeel Holdings and Keralty will each hold an equal 50% shareholding.

Source: Emirates News Agency

Expert: The world is not ready to face another pandemic


Bethlehem – Together – A global health expert warned that the world is not prepared for another health crisis like ‘Covid-19,’ as countries make a final push to agree on a way to move forward with a treaty on the pandemic.

Member states of the World Health Organization met in Geneva on Friday to determine how to continue negotiations on an agreement after the deadline was passed this month.

‘We only hope that in the next few months we will not face another pandemic that finds us in a world that is still not prepared to face a major crisis,’ said Muhammad Ali Butt, a board member of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

A major sticking point in the treaty has been provisions that low- and middle-income countries must receive 20% of tests, treatments and vaccines developed to fight the pandemic, either at non-profit costs or donated.

Ali Butt said this number was reasonable to avoid the scramble for life-saving products, which has left African countries last in line during the Covid-19 c
risis.

The sources said that while talks on the treaty are likely to continue for months or even years, a parallel process to update the current set of rules governing disease outbreaks at the international level is moving closer to an agreement, and it could be signed before the end of the World Health Organization’s annual meeting on Saturday. .

Source: Maan News Agency